Antate is at the forefront of predictive health technology, developing an advanced model to assess the risk of gestational diabetes mellitus (GDM) at the early stages of family planning—long before the typical diagnosis window of 24 to 28 weeks of pregnancy. Our approach integrates multiple data sources, including: Gut microbiome profile along with Biomarker data, Personal health history and Diet and lifestyle factors

Beyond risk prediction, Antate is pioneering the development of cultured microbiome libraries, eliminating reliance on fecal donors and enabling precise control over microbiota composition. Leveraging these innovations, we are creating next-generation bio-therapeutics—including condition-specific full spectrum probiotics—to target metabolic disorders with unprecedented precision.

At Antate, we are shaping the future of maternal-infant health and microbiome-based medicine.

Antate

Org chart

Teams

Offices

Antate

Org chart

Teams

Offices

Related companies